StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) company profile

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

About Alaunos Therapeutics

Pharmaceutical Preparations, SIC 2834

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical enterprise concentrating on the discovery and development of orally administered small-molecule treatments for obesity and metabolic conditions, including metabolic dysfunction-associated steatotic liver disease. The company's lead therapeutic candidate, ALN1003, utilizes a differentiated, non-hormonal, and non-incretin mechanism of action intended to provide an alternative or complementary option to hormone-based incretin therapies. Alaunos previously operated as a clinical-stage oncology biotechnology firm focused on developing adoptive T-cell receptor engineered cell therapies before pivoting away from that portfolio.

The company operates with a single full-time employee and relies on third-party consultants, advisors, and contract development and manufacturing organizations to handle administrative functions, research, and drug substance production. Alaunos conducts its corporate operations from its principal executive offices located in Fort Lauderdale, Florida.

Summary of the business section of Alaunos Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Alaunos Therapeutics, Inc.
Founded
1998
Headquarters
Fort Lauderdale, FL
Address
501 E Las Olas Blvd, Suite 300 33301
Phone
(346) 355-4099
Employees
1, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Tampa, Florida

Stock & identifiers

Ticker
TCRT
Former tickers
ZIOP until Jan 26, 2022
Exchange
Nasdaq
IPO date
Aug 24, 2005
Shares outstanding
3M, Aug 14, 2026
Public float
$9.61M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jul 18, 2024; 1-for-15 reverse, Feb 1, 2024
SEC CIK
1107421
CUSIP
98973P309
ISIN
US98973P3091
FIGI
BBG000FWCC57
Share class FIGI
BBG001SM7BJ6
EIN
84-1475642

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Dale Curtis Hogue Jr.See Remarks, Director–
Holger WeisCEO68,247
Ferdinand GroenewaldVice President of Finance10,775
Melinda LackeyLegal & Administration–
Healthcare Co-Invest VII L.P. FairmountDirector–
Healthcare Fund II L.P. FairmountDirector–
Funds Management LLC FairmountDirector687,789
Peter Evan HarwinDirector–
Robert W. PostmaDirector142,878
Jaime VieserDirector85,914
Michael Allen JermanDirector44,749

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$308.34K$354.48K$296.34K$4–
FY2023$1.72M$1.46M$665.71K$3–
FY2022$1.79M$1.84M$856.93K$6–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Dale Curtis Hogue, Jr.
Interim Chief Executive Officer
$233.97K$59.88K$14.49K$308.34K+540%
Ferdinand Groenewald
Vice President, Finance
–$3.09K$159.22K$162.30K–
Melinda Lackey
Legal & Administration, Corporate Secretary
–$3.09K$427.28K$430.37K-48%
Kevin S. Boyle, Sr.
Former Chief Executive Officer
$317.50K–$75.00K$392.50K-80%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we had one full-time employee and no part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 21, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 13, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 9, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 15, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 2, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 11, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 21, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 4, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 18, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 4, 2022Name changeName changed from ZIOPHARM ONCOLOGY INC to Alaunos Therapeutics, Inc.
Aug 9, 2021Late filingNotification of late filing
Dec 30, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 18, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 30, 2010Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 20, 2006ListingRegistration of securities on an exchange (Form 8-A)
Sep 19, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 19, 2005Name changeName changed from EASYWEB INC to ZIOPHARM ONCOLOGY INC
Aug 16, 2004Late filingNotification of late filing
Mar 31, 2004Late filingNotification of late filing
Mar 31, 2003Late filingNotification of late filing

See a number that looks wrong?